Researchers have developed a novel method to identify aggressive early-stage lung cancers and target drugs known as aurora kinase inhibitors to tumors that are especially likely to respond to them. The findings could lead to great advances in treatment for lung adenocarcinoma, the most common type of lung cancer.
